Stem Cell Clinic

Mesoblasts share price gained another 16% in July. Heres why. – Motley Fool Australia

By Stem Cell Medicine

Motley Fool Australia Share Market News Mesoblasts share price gained another 16% in July. Heres why.

Bernd Struben | August 7, 2020 2:07pm | More on: MSB ASX 200

Biotechnology company Mesoblast limiteds (ASX: MSB) share price added to the strong gains it notched up from April through June, closing up another 16.3% in July. An impressive performance considering the S&P/ASX 200 Index (ASX: XJO) only gained 0.5% in July.

Mesoblasts share price was hammered badly in the wider market sell-off during early COVID-19 lockdown measures, tumbling a gut-wrenching 60% from 23 February through its low on 24 March.

Since its 23 March low, Mesoblasts share price has come roaring back, up 241% by 31 July.

Year-to-date Mesoblasts share price is up 115%, giving the company a market cap of $2.6 billion.

Mesoblast is a regenerative medicine company developing treatments for inflammatory ailments, cardiovascular disease and back pain.

Mesoblast uses its proprietary technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex diseases. The company targets diseases that are resistant to a conventional standard of care and where inflammation plays a central role.

Mesoblast has four phase-3 products nearing registration:

Mesoblasts share price benefited from the companys involvement in treating COVID-19.

In the first week of July, Mesoblast released a promising update on its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L.

The company reported an expanded access protocol (EAP) had been initiated in the United States for the compassionate use of remestemcel-L. Patients who tested positive for the virus aged between 2 months and 17 years with pre-existing cardiovascular issues could access remestemcel-L within 5 days of referral under the EAP.

Mesoblasts financial performance has also been strong. The company recorded a 113% increase in overall revenues for the first 9 months of the 2020 financial year, compared to the first 9 month of the 2019 financial year. Mesoblasts balance sheet was also fortified by a $138 million fund raising in May. The companys next earning report is scheduled to be released on 27 August.

Mesoblasts share price has continued to run higher, up 16% so far in August.

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bernd Struben earned his economics degree in the US. Following several years writing about the tourism industry in the Caribbean, he moved to The Netherlands to cover the EUs booming commercial real estate markets. He moved to Australia in 2010, where he transitioned to analysing the Aussie equity markets. He employs a combination of macro economics and company specific data to gauge what he believes are tomorrows best investments. In his free time, youre likely to find Bernd at the beach or dabbling away on a new work of science fiction.

Read this article:
Mesoblasts share price gained another 16% in July. Heres why. - Motley Fool Australia

National Stem Cell Clinic: Stem Cell Therapy in Miami …

By Stem Cell Clinic

What Are Stem Cells?

The cells in your body have an amazing ability to transform into different types of tissues as required. Some may specialize as muscles, tendons, nerve tissue, or bone. Stem cells are a special type of cell that hasnt specialized yet. These cells are essentially a blank slate, capable of turning into a large number of body tissues.

By harvesting stem cells from your own body, doctors can program these tiny building blocks to become the exact type of tissue you need to heal an injury, be it cartilage for your joints or muscle proteins for repairs.

The first step is to harvest stem cells that are autologous or come from your own body. Bone marrow and fatty adipose tissue contain the largest concentration of stem cells in adults. Once doctors have the correct amount of stem cells, they inject these natural healing factors into the site of your injury along with your blood platelets. This activates the stem cells, causing them to start regenerating damaged tissue.

The possibilities of stem cells for regeneration and repair are virtually limitless, but their effects are especially desirable in areas of the body that were previously believed to be impossible to regenerate, such as cartilage. Here a few situations where stem cell therapy can make a significant difference:

There are a number of reasons why stem cell therapy is so desirable for injury and disease treatment:

At National Stem Cell Clinic (NSCC), we stay at the cutting edge of stem cell treatment. Here are two excellent treatment possibilities using autologous stem cells.

As a high-tech medical care clinic with top surgeons with extensive experience in cutting-edge medical treatments, we offer the most advanced regenerative tissue therapy available. At National Stem Cell Clinic, our expert physicians explain all treatment options available to you, as well as the benefits of each for reaching your personal recovery goals.

With an astonishing 95 percent success rate, we can help athletes make a quick recovery and keep going strong in their career. Stem cell therapy can also provide lasting pain relief for people with arthritis or other chronic pain conditions. To schedule an appointment or request additional information, reach out to us by phone or online.

See the article here:
National Stem Cell Clinic: Stem Cell Therapy in Miami ...

Why cultivated meat is about to have its Tesla Roadster moment – Massive Science

By Stell Cell Research

Almost everything we consider a great invention is, in fact, a series of great inventions. Take the electric car, which was dreamed up long before the gasoline engine, and had numerous rebirths and deaths throughout the 20th century, with a whos who of great companies and inventors trying their hand at new prototypes. Unfortunately, its battery life remained too short and its top speed too slow to compete with the gas-guzzling competition. That is, until California engineer J.B. Straubel invented a new lithium-ion battery that solved both problems. His fateful meeting with Elon Musk in 2003 led to the creation of the Tesla Roadster the beginning of the end for gasoline cars.

Cultivated meat the industry I work in as a scientist has followed a similar trajectory. In a 1931 essay, Winston Churchill already imagined growing meat in a lab without harming animals. This dream has also recently become a reality, driven by constant innovation and growing concerns about the carbon footprint of factory farms. Over the past ten years, I have witnessed it grow from a niche preoccupation into a global effort. But like the old electric car, cultivated meat has since been working through its prototype phase. Whats holding it back? The stem cells that are the driving force behind it run out of steam too quickly for efficient harvesting. The process of combining the necessary fat and muscle cells has proven too unwieldy. The resulting price tag is still too high. These hurdles often dubbed our scalability problem have prevented cultivated meat from making the transition from the lab to the market. Until now.

Today, seven years after Mark Post debuted the first lab-grown hamburger to the world, my company Meatable is unveiling a new invention that could give cultivated meat that final push from prototype to widely available product. Our new patented cell-programming technology, opti-ox, has already shown exceptional promise in overcoming our industrys scalability problems. We are betting that this transition will eventually be looked back on as cultivated meats roadster moment the crucial step that helps our industry get over the hump and into supermarkets, in pursuit of a more ecological world.

But how does our technology work? And what needs to happen next for it to fulfill its revolutionary potential? In what follows, I hope to offer some exclusive insights into this breakthrough and how we got there.

Seven years ago, I was working on the research end of Mark Posts pioneer hamburger project, and I remember feeling immensely proud. News cameras started flocking to our lab in the cardiovascular department of Maastricht University. Perhaps now my mother would stop asking me when I planned to get a real job. Marks famous patty showed the world that cultivated meat was a real and transformative possibility. To those of us working on the back end, the project also illustrated how far we still had to go for its prophecy to be fulfilled. Hundreds of thousands of dollars and tens of millions of cells (and the gargantuan lab space required for processing them) had gone into creating that burger. This was an early introduction to cultivated meats famous scalability problem.

10 layers of culture flasks used in the production of the first cultivated hamburger.

Photo by Daan Luining

In the following years, I was excited to work with start-ups around the world who devoted themselves to scaling up production while bringing down the price. The hope was huge. The success of our collective project could save countless animal lives and offer an ecological alternative to an industry with a deleterious carbon footprint. What needed to be done? I immersed myself in these questions while working as Research Director for Cellular Agriculture non-profit New Harvest, getting an overview of all the great work happening in cultivated meat and a crash course in what was holding us back.

The limitations were innate. Cultivated meat is made of cells, lots of them, ideally a combination of fat and muscle cells. Unfortunately for us, these mammalian cells are innately limited by something called senescence. Anatomist Leonard Hayflick discovered it in 1961: mammalian cells can only divide between forty to sixty times before they cannot divide any more. This limitation meant that cultivated meat makers had to keep harvesting and introducing new animal cells a highly inefficient process.

We have long known of a possible way of overcoming this hurdle: using pluripotent cells. Discovered by Nobel Prize winner Shinya Yamanaka in 2006, these cells are special because they are able to divide endlessly, never running out of steam. The question was: how could we turn them into the specific cells we needed, muscle and fat? This requires shepherding the development of a cell all the way to adulthood. The available methods to do this have been time- and space-consuming. Until now.

In the years after Mark Posts famous hamburger, another Mark was (unwittingly) doing research that would prove crucial to the advancement of cultivated meat. Mark Kotter, a neurosurgeon and principal investigator at Cambridges STEM Cell Institute, spent years trying to reprogram pluripotent cells for neurological application.

Starting in 2014, Kotter discovered a way to build specific transcription factors into the pluripotent cells DNA. Every cell in the population turned into exactly what he wanted. He couldnt believe his eyes. He had his graduate students re-run the experiment over and over. Every time, 100% of the pluripotent cells were converted to oligodendrocytes. He had created pure culture of cells from stem cells, which was unheard of thus far.

This turned out to have unintended applications, when I was introduced to Mark in 2016 through a New Harvest fellow. Mark had never heard of cultivated meat, but it took me maybe five minutes to convince him that it was exactly what the world needed. I realized just as quickly that opti-ox could be a game-changer for our industry. In 2018, we co-founded Meatable with our CEO Krijn de Nood, and started applying Marks technology to reprogramming pig cells. Soon, all our hard work started to pay off.

In several experiments earlier this year, we have finally proved that we can grow pork using opti-ox technology on a porcine pluripotent cell. For the first time in history, we have successfully differentiated pluripotent cells into fat and muscle with unprecedented speed and efficiency.

Pluripotent pork cells differentiated into fat (red) and muscle (green) in 7 days.

This process will allow us to grow fat and muscle together. An answer to an elusive problem: adult muscle and fat stem cells require vastly different nearly opposite environments to thrive. With pluripotent stem cells, muscle and fat cultures start from the same type of cell, so they can be grown side-by-side. No mixing required afterwards. The two ingredients can be grown together as they naturally do in animal meat. This, too, is a game changer. It will allow us to create a controlled large-scale process on both ends.

We believe that our opti-ox technology will be the battery pack that helps propel cultivated meat into the mainstream. Combining two breakthrough technologies that use cellular reprogramming in a way that has never been done before, the next test will be our first prototype sausage, followed by a pork chop. We then intend to continue our experiments with beef.

This technology will help us produce meat that's faster to market, higher quality, and more cost effective. More importantly, it will bring us one step closer to our greater goal: separating meat consumption from the death and carbon of factory farms, just as electric cars allowed us to drive without polluting the environment.

This reality may still be 5 years off, but in science that is little more than a blink of an eye. In the long-term, our success depends not only on scaling technological boundaries, but on challenging social perceptions, and having the courage to rethink one of humanitys oldest habits. The possibilities are humbling.

Follow this link:
Why cultivated meat is about to have its Tesla Roadster moment - Massive Science

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market to Reach a Value of Approximately US$ 450.5 Mn by the End of 2026 – Science Examiner

By Stell Cell Research

Transparency Market Research (TMR) has published a new report titled Platelet Rich Plasma & Stem Cell Alopecia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, the global platelet rich plasma & stem cell alopecia treatment market was valued at approximately US$ 250Mn in 2017. The market is anticipated to reach a value of US$ 450.5 Mn by 2026, expanding at a higher single digit CAGR during the forecast period. Rise in awareness about platelet rich plasma & stem cell alopecia treatment and increase in funding for alopecia treatment research and stem cell research are expected to augment the global market from 2018 to 2026. The global platelet rich plasma & stem cell alopecia treatment market is projected to expand, owing to a rise in the incidence of alopecia and technological advancements.

Rise in Awareness about Platelet Rich Plasma Therapies and Stem Cell Therapies is Propelling the Global Alopecia Treatment Market

The global platelet rich plasma & stem cell alopecia treatment market is expanding at a high growth rate, driven by an increase in awareness about platelet rich plasma & stem cell therapies for treating many types of alopecia. The prevalence of various types of hair loss is increasing rapidly across the world, due to a rise in the geriatric population, anxiety, vaccination, side effects of drugs, etc.. A rise in the incidence of autoimmune hair loss disorders such as alopecia is boosting the platelet rich plasma & stem cell alopecia treatment market.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55800

According to a report in the International Journal of Endocrinology and Metabolism, 2013, female pattern hair loss (FPHL), which is also known as female androgenetic alopecia, is a common condition afflicting millions of women across the world.

Increase in Funding for Alopecia Treatment Research and Stem Cell Research

Stem cells hold promise for the treatment and cure of more than 70 major diseases, including alopecia and other conditions that affect millions of people worldwide. Several private and government organizations are supporting funding for stem cell research. According to Change.org, Inc., in the U.S., 64% of people support federal funding of research on the treatment of chronic diseases using stem cells taken from human embryos. Internationally, stem cell research is supported by significant government investments, with Asia being one of the most favorable regions. Stem cell research funding by the National Institutes of Health (NIH) has increased 17% from US$ 1.2 Bn in 2013 to US$ 1.5 Bn in 2016. In 2017, nonprofit organization Alopecia UK donated US$ 0.6 Mn to the University of the West of Scotland for the development of early treatment to prevent the progression of alopecia areata. Research conducted by the university aims at developing a treatment for alopecia areata using a nonchemical stem-cell based technology based on nanovibrations known as nanokicking.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

North America Dominates the Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market owing to a Rise in Technological Advancements and Prevalence of Alopecia

North America dominates the global platelet rich plasma & stem cell alopecia treatment market, owing to technological advancements, investments in research & development, and developed health care infrastructure. As per research, in 2015, 21% of women suffered from alopecia in the U.S, which supports the fact that alopecia has a higher prevalence in the country. Moreover, development of innovative products and increase in demand for products among the population in the region are contributing factors for the dominance of North America in the platelet rich plasma & stem cell alopecia treatment market.

Expansion in the Contract Research Industry Offers Significant Opportunities for Companies to Invest in Clinical Trials for Alopecia Treatment

Small and large biopharmaceutical companies have become increasingly reliant on contract research organizations (CRO) and other clinical services specialists to provide research services for their R&D operations. There are numerous government-funded medical and pharmaceutical institutions, with state-of the-art facilities, that can serve as ideal centers for multicentered clinical trials. Companies are expanding their footprints in developing countries, mainly in Asia Pacific. R&D costs in India are substantially lower as compared to those in developed countries. It is possible to conduct both new drug discovery research and novel drug delivery system programs at competitive rates. India offers cost efficiency, as the cost of conducting a trial in the country is 50% to 75% lower compared to that in the U.S. or the European Union.

Purchase Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

Investments, Mergers & Acquisitions, and PARTNERSHIPS by Key Players are Driving the Platelet Rich Plasma & Stem Cell Alopecia Treatment Market

Key players dominating the global platelet rich plasma & stem cell alopecia treatment market are Kerastem, Eclipse, Regen Lab SA, STEMCELL Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Major players are focusing on mergers and acquisitions and are investing in the development of platelet rich plasma & stem cell alopecia treatment and making them available to the patient population. For instance, companies such as Stemcell technologies, Inc. highly focus on partnerships with research institutes to develop new advanced products. In 2019, Kerastem signed a partnership agreement with Myungmoon Bio Co., Ltd., a South Korea-based health care company focused on bringing innovative regenerative therapies.

More Trending Reports by Transparency Market Research

Pregnancy Detection Kits Market: https://www.biospace.com/article/pregnancy-detection-kits-market-swot-analysis-of-major-industry-segments/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Link:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market to Reach a Value of Approximately US$ 450.5 Mn by the End of 2026 - Science Examiner

Startup Accelerator: Volumetric Aims to Be the Tissue Bioprinting Farm of the Future – 3DPrint.com

By Stem Cell Medical Center

Startup Accelerator is an article series with a focus on new and exciting companies in the 3D printing space, in which 3DPrint.com speaks to startup leadership about their unique technologies and businesses.

At one of the largest medical cities in the world, a startup is pushing the limits of bioprinting technology by harnessing the power and precision of light to structure living tissue. Born as a spin-off out of Rice University, Volumetric has come a long way since being founded in 2018, advancing the creation of biomaterials and a biofabrication platform for cancer research, regenerative medicine, and human organ replacement initiatives worldwide.

Efforts to reproduce the vascular architecture in the body have led Jordan Miller, an assistant professor of bioengineering at Rice University, and one of his bioengineering graduate students, Bagrat Grigoryan, to create Volumetric. The duo has been focusing on innovation that allows scientists to create exquisitely entangled vascular networks that mimic the bodys natural passageways for blood, air, lymph, and other vital fluids. Originally dubbed SLATE, which is short for stereolithography apparatus for tissue engineering, the new open-source bioprinting technology uses additive manufacturing to make soft hydrogels and is the basis for the firms commercially available technology.

While most of the attention in tissue engineering typically goes to the progress being done on cells, Volumetric is playing a key role focusing on the extracellular space, that is, what happens outside cells. If we think about solid organs in the body, like the liver, they are very complex biologically, with an intricate blood vessel structure. What is most apparent in that complexity, is the complexity of the architecture, Miller said to 3DPrint.com. There is a fantastic progress on the cell side as researchers are finding newer and better ways to grow cells, differentiate cells, taking stem cells, and making them into organ-specific functions, however, everything outside of the cell is part of our expert research.

With so much research to back up their development, Miller and Grigoryan were confident that commercializing the technology they developed at the lab was the next step. After licensing, it became the basis for the LumenX bioprinters that are manufactured through a partnership between Volumetric and Cellink one of the worlds leading biotechnology companies.

Designed as an entry-level platform to build vasculature, the LumenX achieves complex branching and tapering of vessels. Moreover, the founders claim that the device photographically cures entire layers at once to crosslink structures 50 times faster than other printing methods. This process is performed with incredible resolution, leveraging more than one million simultaneous points of light to bioprint microscopic features down to 200 microns.

As we were creating this technology at the research lab, we immediately began thinking about its potential in society, suggested Miller. We understood that we wanted to take our basic research out of the lab and into the clinical practice where it would have an impact. So, to translate our technology, we knew that it would have to be commercialized, to stand up as part of a business model that could survive. That is when our research became bigger than just an academic paper. Whereas an academic paper can have an impact on peoples mindsets, a commercialized product can have a big impact directly on peoples lives.

The LumenX by Volumetric and Cellink (Image courtesy of Cellink/Volumetric)

So, the company was born out of huge progress that the team made at the lab, plus, dozens of requests from fellow researchers who wanted to use Volumetrics technology to develop their own projects. Miller and Grigoryan licensed their own intellectual property out of the university and into the company Volumetric, and they have been using it to sell bioinks and bioprinters ever since.

This is a very exciting opportunity, because when there is a scientific finding in a research lab, it is not always obvious how it can translate into a direct impact for society, but commercialization is a way to address this issue.

Creating high-quality biomaterials and 3D biofabrication platforms are part of Volumetrics mission. Aside from LumenX, Volumetric founders also developed the only cell-compatible biomaterials on the market for light-based printing, ideal for creating vascular networks within cell-laden hydrogels or lab-on-a-chip devices. The company is pushing the limits in the field of bioprinting by incorporating the unique ability of its technology to print complex, 3D vascularized living tissue, one of the most advanced and hard to mimic tissues in the field.

Quote request

Are you looking to buy a 3D printer or 3D scanner? We're here to help. Get free expert advice and quotes from trusted suppliers in your area.

Powered by Aniwaa

Multilayer 3D microfluidic plastic chips can be rapidly printed in minutes with the LumenX (Image courtesy of Volumetric/Cellink)

After witnessing successful university spin-off companies emerge around the world, one thing is clear, a major challenge for many startups is related to funding. However, Miller and Grigoryan were able to tap into the National Science Foundation (NSF) and its Innovation Corps program to get most of the funding for their collaboration, and in just two years, the startup has become a strong seller of specialized printers and hydrogel bioinks for printing tissue constructs.

Another great advantage of the company is its location, right at the heart of the Texas Medical Center (TMC), in Houston, working out of Johnson & Johnson Innovation (also known as JLABS), a global network ecosystem that empowers inventors across a broad healthcare spectrum to accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. It is by far one of the largest medical centers worldwide and a place where clinicians and surgeons are eager to see bioprinting technology, like Volumetrics, translated from bench to bedside.

Clinicians see first hand the need and urgency for replacement tissues to work. Which led us to craft a clinical strategy for a potential organ we could produce, how we would go about producing it, how we would design the clinical trials, and what early studies need to be complete in order to get there, Miller described. Our work goes beyond just theories, its about actually having surgeons work with our tissue scaffolds, to determine whether the material can be implantable. We need to know if they can put a suture through it and pull without the suture coming right out. We know that our work involves thinking about optimizing the material for the cells, but also for the surgeon.

Although Volumetric still has a lot of work ahead, more than 20 years of experience in bioengineering are helping Miller find a balance for both cells and surgeons to strive.

Jordan Miller and Bagrat Grigoryan in 2018 after founding Volumetric (Image courtesy of Volumetric)

Miller has a very particular vision for Volumetrics future, in part because he considers that the technology is highly scalable. He believes that what lies ahead for bioprinting companies like Volumetric is similar to what happened with the Prague-based open-source 3D printing company Prusa, except that in this case, its for biofabrication.

They [Prusa] are using 3D printers to make the parts that they need, relying on a print farm that is running non-stop, and churning out lots of high-value pieces. That is the perfect analogy of what we see for the future of regenerative medicine, where companies, like Volumetric, will develop large bioprinting farms, scaling out living tissue which could eventually become organ and tissue replacements for people.

The researchers at Volumetric have been working flat-out to provide a blood vessel structure for engineered tissue constructs. This is one of the most difficult feats in the filed, as researchers working towards the biofabrication of artificial vasculature have encountered several challenges to create the functional vessel-like structures that can supply oxygen and nutrients to cells of 3D bioengineered tissues. However, Millers advances at his laboratory at Rice and Volumetric led him to create the first bioprinting technology that addresses the challenges of multivascularization:

Right now, the field of regenerative medicine has the most potential its ever had, we know much more about how cells interact with materials than before, and our technology platform is allowing people to go deeper into biology and develop new materials to move the field forward.

More here:
Startup Accelerator: Volumetric Aims to Be the Tissue Bioprinting Farm of the Future - 3DPrint.com

Covid-19 Impact on 2021-2026 Stem Cell Manufacturing Market Segmentation, Analysis by Recent Trends, Development & Growth by Regions – Owned

By Stell Cell Research

The presented study maps the growth trajectory of the Global Stem Cell Manufacturing Market by thoroughly assessing the various factors that are expected to influence the future prospects of the Stem Cell Manufacturing Market. According to the report published, the Stem Cell Manufacturing Market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2026 with a CAGR growth of ~XX% during the forecast period (2014-2026). A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Stem Cell Manufacturing Market is provided in the report. Further, an overview and introduction of the Stem Cell Manufacturing Market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Research Objectives: In this challenging situation, all the players in Stem Cell Manufacturing Market are looking for outlook of Stem Cell Manufacturing Market. Below are main objectives of Stem Cell Manufacturing Market:

To understand the Stem Cell Manufacturing Market growth, future forecast, sales volume, market opportunity, and key players. To understand the Stem Cell Manufacturing Market in North America, Europe, Asia-Pacific, Southeast Asia, MEA & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. Market forecast based on type, application, and key regions.

>>> Get PDF Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, List of Tables & Figures, Chart) @

The Stem Cell Manufacturing Market Report Covers These Companies: (Thermo Fisher Scientific (US), Merck Group (Germany), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Miltenyi Biotec (Germany), Takara Bio Group (Japan), STEMCELL Technologies (Canada), Pharmicell (South Korea), Osiris Therapeutics (US), Anterogen (South Korea), Cellular Dynamics International (US), MEDIPOST (South Korea), Lonza Group (Switzerland), Holostem Terapie Avanzate (Italy), Pluristem Therapeutics (Israel))

COVID 19 Impact on Stem Cell Manufacturing Market

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. Under COVID-19 Outbreak, how the Stem Cell Manufacturing Market Industry will develop is also analyzed in detail in Chapter 1.7 of the report. In Chapter 2.4, we analyzed industry trends in the context of COVID-19. In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets. In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries. In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

The Stem Cell Manufacturing Market report highlights market opportunities and competitive scenarios for Stem Cell Manufacturing on a regional and global basis. Market size estimation and forecasts have been provided based on a unique research design customized to the dynamics of the Stem Cell Manufacturing market. The Stem Cell Manufacturing market has been segmented by type (HSCs, MSCs, iPSCs, ESCs, Instruments, Media, Consumables), application (Research, Target Identification, Therapy (Autologous, Allogeneic), Cell Banks). Historic back-drop for Stem Cell Manufacturing market has been analyzed according to organic and inorganic developments to provide precise market size estimations. Also, key factors impacting the growth of the Stem Cell Manufacturing market have been identified with potential gravity.

Regional Insights of Stem Cell Manufacturing Market

In terms of geography, this research report covers nearly all major regions of the world, such as North America, Europe, South America, the Middle East, and Africa, and the Asia Pacific. Europe and North America are expected to increase over the next few years. Stem Cell Manufacturing markets in the Asia Pacific region are expected to grow significantly during the forecast period. State-of-the-art technology and innovation are the most important characteristics of North America and the main reason the United States dominates the world market. The Stem Cell Manufacturing market in South America is also expected to grow in the near future.

>>> To get Incredible Discounts on this Premium Report, Click Here @ https://www.reporthive.com/2392455/check_discount

Table of Contents

Report Overview: It includes major players of the global Stem Cell Manufacturing (COVID-19) Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Stem Cell Manufacturing market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Stem Cell Manufacturing market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the global Stem Cell Manufacturing market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Stem Cell Manufacturing market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the global Stem Cell Manufacturing market.

Market by Application: Here, various application segments of the global Stem Cell Manufacturing market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Stem Cell Manufacturing market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Stem Cell Manufacturing market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the global Stem Cell Manufacturing market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Stem Cell Manufacturing market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

>>> Make an enquiry before buying this report @ https://www.reporthive.com/2392455/enquiry_before_purchase

Why Report Hive Research:

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc.

Contact Us:

Report Hive Research 500, North Michigan Avenue, Suite 6014, Chicago, IL 60611, United States Website: https://www.reporthive.com Email: [emailprotected] Phone: +1 312-604-7084

Read more from the original source:
Covid-19 Impact on 2021-2026 Stem Cell Manufacturing Market Segmentation, Analysis by Recent Trends, Development & Growth by Regions - Owned

Cell Transplantatio Therapy Market Global Research and Analysis 2020 – Owned

By Stell Cell Research

Global Cell Transplantatio Therapy Market research report published bymarket insight reportsexplores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market and divides the Market into several parameters.

This Cell Transplantatio Therapy Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes the projected growth of the global market for the years from 2020 to 2025. This research report has been aggregated on the basis of static and dynamic aspects of the businesses.

Click Here to Get Sample PDF Copy of Latest Research on Cell Transplantatio TherapyMarket 2020:

https://www.marketinsightsreports.com/reports/08052204047/global-cell-transplantatio-therapy-market-growth-status-and-outlook-2020-2025/inquiry?Mode=18

The prominent players in the Global Cell Transplantatio Therapy Market:

Gilead Sciences, Guanhao Biotech, Novartis, Vericel Corporation, Vcanbio, Osiris, Beike Biotechnology, Fujifilm Cellular Dynamics, Golden Meditech, JCR Pharmaceuticals and Others.

It further provides the profile reviews of the leading participants, their overall market shares in the global market, business strategies they have adopted, and the latest developments in their respective business in a bid to enhance the decision-making capability of the readers.

The Cell Transplantatio Therapy market can be divided based on product types and Its sub-type, major applications and Third Party usage area, and important regions.

This report segments the Global Cell Transplantatio Therapy Market on the basis ofTypesare:

Stem Cell

Non-Stem Cell

On the basis ofApplication,the Global Cell Transplantatio Therapy Market is segmented into:

Hospitals

Clinics

Others

SPECIAL OFFER: AVAIL UPTO 20% DISCOUNT ON THIS REPORT:

https://www.marketinsightsreports.com/reports/08052204047/global-cell-transplantatio-therapy-market-growth-status-and-outlook-2020-2025/discount?Mode=18

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Cell Transplantatio Therapy Market these regions, from 2020 to 2025 (forecast), coveringNorth America, Europe, China, Japan, Southeast Asia, India, North America(USA, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)AsiaPacific(China, Japan, Korea, India and Southeast).

Significant Features, those are under Offering and Key Highlights of the Reports:

Detailed overview of Cell Transplantatio Therapy Market Changing market dynamics of the industry In-depth market segmentation by Type, Application, etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Cell Transplantatio Therapy Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

The research includes historic data from 2015 to 2019 and forecasts until 2025 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, the Cell Transplantatio Therapy market report offers a complete and detailed study of global Cell Transplantatio Therapy market by using numerous analytical tools and models such as SWOT analysis, investment return analysis, and porters five forces analysis which are useful for beginners to access the upcoming opportunities. After exploring the market insights through primary and secondary research methodologies, if anything is required except than this, market insight reports will provide customization as per specific demands.

Click the link to Purchase This Full Report @:

https://www.marketinsightsreports.com/report/purchase/08052204047?mode=su?Mode=18

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

Note:- All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Read the original:
Cell Transplantatio Therapy Market Global Research and Analysis 2020 - Owned

Future Technological Prospects of Stem Cell Assay Market To 2030 – Owned

By Stem Cell Medicine

The research report published by PROPHECY MARKET INSIGHTS encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Stem Cell Assay market over the forecast period (2019-2029).

The predictions mentioned in the Stem Cell Assay market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Stakeholders Benefit:

The report on the Stem Cell Assay market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3910

We dont know what lies ahead of this COVID-19 Pandemic crises. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

Segmentation Overview:

Global Stem Cell Assay Market, By Type:

Global Stem Cell Assay Market, By Kit:

Global Stem Cell Assay Market, By Detection:

Global Stem Cell Assay Market, By Instruments:

Global Stem Cell Assay Market, By Application:

Global Stem Cell Assay Market, By End User:

The Stem Cell Assay research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Assay market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis:

Different geographical areas are studied deeply and an economic scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Request discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/3910

Key Questions Answered in Report:

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Stem Cell AssayMarket Key Players:

GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read this article:
Future Technological Prospects of Stem Cell Assay Market To 2030 - Owned

Biobanks Market Projected to be Resilient During 2025 Owned – Owned

By Stem Cell Medicine

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market includeBioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original:
Biobanks Market Projected to be Resilient During 2025 Owned - Owned

In the clinic for Aug. 6, 2020 | 2020-08-06 – BioWorld Online

By Stem Cell Clinic

Company Product Description Indication Status Phase I Dicerna Pharmaceuticals Inc., of Lexington, Mass. RG-6346 RNAi targeting hepatitis B virus mRNA Chronic hepatitis B virus infection In group C, 9 of 10 participants who received RG-6346 and a nucleoside analogue and completed the treatment period achieved 1 log10 IU/mL reduction in hepatitis B surface antigen (HBsAg) at day 112; mean reduction in HBsAg at day 112 was 1.39 log10 IU/mL for the 1.5-mg/kg dose, 1.80 log10 IU/mL for the 3-mg/kg dose and 1.84 log10 IU/mL for the 6-mg/kg dose Dicerna Pharmaceuticals Inc., of Lexington, Mass. Nedosiran RNAi targeting lactate dehydrogenase Primary hyperoxaluria 1, 2 and 3 (PH1, PH2 and PH3) In the Phyox3 open-label extension, 8 of 8 patients with PH1 achieved normalization or near-normalization urinary oxalate levels (Uox) at day 120 with a mean Uox of 0.404 mmol/1.73m2 BSA/24 hr; 1 of 3 patients with PH2 achieved normalization of Uox Personalized Stem Cells Inc., of Poway, Calif. PSC-01 Adipose-derived stromal vascular fraction cells Knee osteoarthritis Completed enrollment in the study; data expected by the end of 2020 Precigen Triple-Gene, a unit of Precigen Inc., of Germantown, Md. INXN-4001 Nonviral plasmid expressing SDF-1alpha, VEGF165 and S100A1 Chronic heart failure Half of the 10 patients had a 5-point improvement in their total KCCQ score 6 months after treatment; 4 of 8 evaluable patients had a >50-meter improvement in their 6-minute walk time at 6 months Tessa Therapeutics Pte Ltd., of Singapore CD30 CAR T Autologous cell therapy Relapsed/refractory Hodgkin lymphoma For the 41 patients, 1-year survival was 94% in phase I/II study; of patients with complete responses, 61% had no evidence of recurrence after 1 year Phase II Bioaegis Therapeutics Inc., of Morristown, N.J. rhu-pGSN Recombinant human plasma gelsolin Hospitalized patients with severe COVID-19 pneumonia Enrolled first patient in study testing 3 doses of the drug; primary endpoint is survival without organ failure and without mechanical ventilation, vasopressors or dialysis on day 14 Idorsia Pharmaceuticals Japan, unit of Idorsia Ltd, of Allschwil, Switzerland Daridorexant Dual orexin receptor antagonist Insomnia In dose-confirmation study in 47 adults in Japan, study drug showed dose-dependent decrease in wake after sleep onset (WASO) at day 1 and 2 and decreased latency to persistent sleep in dose-dependent manner; improvements seen on measures such as subjective WASO, subjective latency to sleep onset and subjective total sleep time Medicinova Inc., of La Jolla, Calif. Ibudilast (MN-166) Phosphodiesterases 4 and 10 inhibitor Alcohol use disorder Drug reduced the number of heavy drinking days compared to placebo (p=0.03) and attenuated alcohol cue-elicited activation in the bilateral ventral striatum (p=0.02) Nordic Nanovector ASA, of Oslo, Norway Betalutin CD37-targeting antibody-radionuclide conjugate Relapsed/refractory follicular lymphoma Independent review committee recommended company focus on the 15-MBq/kg Betalutin dosage arm and discontinue the 20-MBq/kg dose Phase III Boehringer Ingelheim International GmbH, of Ingelheim, Germany Ofev (nintedanib) Tyrosine kinase inhibitor Chronic fibrosing interstitial lung diseases with a progressive phenotype In the Inbuild study, at 52 weeks, 43.4% of patents taking Ofev had a >5% absolute decline in forced vital capacity (FVC), compared to 55% of patients taking placebo; >10% FVC was seen in 28.3% and 36.6% of patient taking Ofev and placebo, respectively Levo Therapeutics Inc., of Chicago LV-101 (intranasal carbetocin) Oxytocin-receptor agonist Prader-Willi syndrome Primary endpoint for the 9.6-mg dose of LV-10 was not met; 3.2-mg dose improved the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score (p=0.016); HQ-CT scores for combined doses produced a p-value of 0.055; 3.2-mg dose also improved clinical global impression of change (p=0.027) and the PWS Anxiety and Distress Behaviors Questionnaire (p=0.027) Novartis AG, of Basel, Switzerland Ofatumumab Monoclonal antibody targeting CD20 Relapsing forms of multiple sclerosis Data published in The New England Journal of Medicine showed drug reduced annualized relapse rate by 51% and 58% compared to teriflunomide in the Asclepios I and II studies, respectively (p<0.001 for both); drug reduced risk of confirmed disability worsening at 3 months by 34% (p=0.002) and at 6 months by 32% (p=0.01) Rafael Pharmaceuticals Inc., of Cranbury, N.J. CPI-613 (devimistat) Targets the mitochondrial tricarboxylic acid cycle Metastatic pancreatic cancer Completed target enrollment of 500 patients in the Avenger 500 study

Notes

For more information about individual companies and/or products, see Cortellis.

Read more:
In the clinic for Aug. 6, 2020 | 2020-08-06 - BioWorld Online

→←